Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260909 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Non-ergot dopamine agonist with in-vitro activity at D2-family receptors and greater affinity for D3 than D2 or D4. The precise mechanisms in Parkinson disease and restless legs syndrome are unknown.
On both cards: Common side effects — Nausea; Insomnia
Only on the Pramipexole card: Used for — Parkinson disease in adults; Moderate-to-severe primary restless legs syndrome in adults · Common side effects — Dizziness; Somnolence; Hallucinations · Warnings — Falling asleep during daily activities; Orthostatic hypotension; Impulse control / compulsive behaviors · Interactions — Dopamine antagonists (neuroleptics, metoclopramide)
Mechanism: Animal studies suggest reduced polysynaptic responses and blocked post-tetanic potentiation; the mechanism of action remains unknown.
On both cards: Common side effects — Nausea; Vomiting
Only on the Carbamazepine card: Used for — Complex partial seizures, generalized tonic-clonic seizures, or mixed patterns including these types; absence seizures do not appear to be controlled by carbamazepine · Common side effects — Dizziness; Drowsiness; Unsteadiness · Warnings — Bone marrow depression history (contraindicated); Tricyclic compound sensitivity (contraindicated) · Interactions — MAO inhibitors; Nefazodone (contraindicated)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera